fbpx

Mesothelioma Diagnosis- Oncologists who Specialize Can Make a Difference

Share Button

The Study Linked and Excerpted Below Points to the Importance of Newly Diagnosed Patients Working with Oncologists Who Specialize in Treating Mesothelioma

It only makes sense the oncologists who have the most experience with a certain type of cancer treat patients with that specific cancer more effectively. Mesothelioma is a complicated type of incurable cancer that requires an experienced specialist.

For the record, I don’t believe in toxic therapy for any type of cancer- long-term. Unfortunately, toxic chemotherapy can be a necessary evil.

Rather, I should say, the right kind of chemo in the right dosages with the right integrative therapies can be the best option for you. After all, chemo and radiaton can fight your cancer yet cause collateral damage to your body.

 

The study below cites a therapy that may improve the mesothelioma standard.

I am a long-term survivor of an incurable cancer called multiple myeloma. While myeloma is a very different cancer than mesothelioma it is clear to me that these two complicated cancers have a lot in common. If you have been diagnosed with mesothelioma you owe it to yourself to learn about both conventional and evidence-based non-conventional therapies to fight your cancer. You also owe it to yourself to work with a specialist who understands the type of study linked below.

To learn more about those integrative therapies that have proven efficacy of meso killing properties or the ability to enhance the efficacy of specific chemotherapies, scroll down the page, post a question or comment and I will reply ASAP.

Thank you,

David Emerson

  • Long-term Cancer Survivor
  • Cancer Coach
  • Director PeopleBeatingCancer

Recommended Reading:


Microspheres targeted with a mesothelin antibody and loaded with doxorubicin reduce tumor volume of human mesotheliomas in xenografts

Background

Malignant mesotheliomas (MMs) are chemoresistant tumors related to exposure to asbestos fibers. The long latency period of MM (30-40 yrs) and heterogeneity of tumor presentation make MM difficult to diagnose and treat at early stages. Currently approved second-line treatments following surgical resection of MMs include a combination of cisplatin or carboplatin (delivered systemically) and pemetrexed, a folate inhibitor, with or without subsequent radiation. The systemic toxicities of these treatments emphasize the need for more effective, localized treatment regimens.

Results

Targeted therapy (APMS-MB-DOX at 0.05 mg/kg) was more effective than DOX low (0.05 mg/kg) and less toxic than treatment with DOX high (0.2 mg/kg). It also resulted in the reduction of tumor volume without loss of animal health and weight, and significantly decreased tumor cell proliferation. High pressure liquid chromatography (HPLC) of tumor tissue confirmed that APMS-MB-DOX particles delivered DOX to target tissue.

Conclusions

Data suggest that targeted therapy results in greater chemotherapeutic efficacy with fewer adverse side effects than administration of DOX alone. Targeted microparticles are an attractive option for localized drug delivery.”

Mesothelioma- Multimodal approach may triple overall survival-

“it is widely accepted that best long term results after treatment for malignant pleural mesothelioma are achieved when several modalities are combined.”

Mesothelioma (meso) is an aggressive cancer with a poor overall survival outlook. Therefore I look at mesothelioma as I do my own incurable cancer, multiple myeloma. I have always balanced conventional therapies (FDA approved) with evidence-based, non-conventional therapies. The studies linked and excerped below cite mesothelioma therapies that your oncolosgist might not have discussed with you.

I first tried conventional chemo, radiation and an autologus stem cell transplant. Remission, relapse, remission, then terminal. And then I went on to try a host of non-conventional therapies.

Light-Based Therapy Extends Mesothelioma Survival

“The newest research on photodynamic therapy appears to confirm what multiple recent studies have found – that PDT is a safe and effective way to prolong survival in pleural mesothelioma patients after surgery…

“After two decades of clinical studies, intrapleural photodynamic therapy after surgical resection became a safe treatment that significantly improved the survival of patients,”

Meso patients undergoing PDT get an injection of a photosensitizing drug several days before treatment. The most popular drug for this purpose is porfimer sodium (Photofrin), which has been recognized with orphan drug status by the FDA for its potential in treating meso. Meso cells absorb more of the photosensitizer and retain it longer than healthy cells, which is one of the reasons PDT produces fewer side effects than chemotherapy or radiation

A 2012 study of 97 pleural meso patients found that PDT after pleurectomy tripled survival times from around a year to more than 3 years. Other recent studies have produced encouraging results by combining PDT with chemotherapy, suggesting that the two treatments may work synergistically to fight meso.”

 

Leave a Comment:

1 comment
Add Your Reply